Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH

MLA

Han Wang, et al. “Low Dose Ruxolitinib plus HLH-94 Protocol: A Potential Choice for Secondary HLH.” Seminars in Hematology, vol. 57, no. 1, Feb. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9c057033f22178cb666d595234c96545&authtype=sso&custid=ns315887.

APA

Han Wang, Wei Huang, Jia Gu, Xue Liang, Xiao Mao, & Zhiqiong Wang. (2018). Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH. Seminars in Hematology, 57(1).

Chicago

Han Wang, Wei Huang, Jia Gu, Xue Liang, Xiao Mao, and Zhiqiong Wang. 2018. “Low Dose Ruxolitinib plus HLH-94 Protocol: A Potential Choice for Secondary HLH.” Seminars in Hematology 57 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9c057033f22178cb666d595234c96545&authtype=sso&custid=ns315887.